Atara Biotherapeutics Inc (ATRA) reported quarterly earnings results on Thursday, May-5-2016. The company said it had a profit of $-0.58 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.02. Analysts had a consensus of $-0.60. During the same quarter in the previous year, the company posted $-0.42 EPS.
Atara Biotherapeutics Inc closed down -0.67 points or -4.01% at $16.02 with 2,57,497 shares getting traded on Wednesday. Post opening the session at $16.5, the shares hit an intraday low of $15.48 and an intraday high of $16.55 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Apr 27, 2016, Isaac E. Ciechanover (Chief Executive Officer) sold 1,300 shares at $20.14 per share price. According to the SEC, on Mar 17, 2016, Eric Dobmeier (director) purchased 3,000 shares at $13.85 per share price. On Feb 18, 2016, Carol Giltner Gallagher (director) sold 1,183 shares at $16.30 per share price, according to the Form-4 filing with the securities and exchange commission.
Atara Biotherapeutics Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics for serious unmet medical needs with an initial focus on muscle wasting conditions and oncology. The Company’s lead product candidate PINTA 745 is a peptibody that binds myostatin and inhibits its corresponding signal transduction thereby blocking the negative regulation of skeletal muscle growth. PINTA 745 is in a Phase II clinical trial. The Company’s second product candidate STM 434 which is in a Phase I clinical study is a soluble ActR2B receptor that binds Activin A. The Company has five additional product candidates: ATA 842 a humanized antibody targeting myostatin; ATA 777 a fully human antibody targeting Activin A; ATA M43 a fully human anti-ActR2A/2B monoclonal antibody; STM 217 a soluble ActR2B receptor-IgG Fc fusion protein and a close analog of STM 434 and ActR2B5 a soluble ActR2B receptor that can be fused to an IgG Fc receptor.